Processa Pharmaceuticals Inc (PCSA)
1.67
+0.13
(+8.44%)
USD |
NASDAQ |
Apr 17, 16:00
1.66
-0.01
(-0.60%)
After-Hours: 05:39
Processa Pharmaceuticals Cash from Financing (TTM): 6.269M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 6.269M |
September 30, 2023 | 6.246M |
June 30, 2023 | 6.263M |
March 31, 2023 | 6.263M |
December 31, 2022 | -0.3888M |
September 30, 2022 | -0.2039M |
June 30, 2022 | -0.3538M |
March 31, 2022 | -0.3769M |
December 31, 2021 | 9.799M |
September 30, 2021 | 27.03M |
June 30, 2021 | 27.06M |
March 31, 2021 | 27.75M |
December 31, 2020 | 17.87M |
September 30, 2020 | 1.302M |
June 30, 2020 | 1.963M |
March 31, 2020 | 1.583M |
December 31, 2019 | 1.701M |
September 30, 2019 | 0.6807M |
June 30, 2019 | 0.2857M |
March 31, 2019 | 2.739M |
December 31, 2018 | |
September 30, 2018 | |
June 30, 2018 |
Date | Value |
---|---|
March 31, 2018 | |
December 31, 2017 | 2.425M |
September 30, 2017 | 0.327M |
June 30, 2017 | 0.075M |
March 31, 2017 | 0.00 |
December 31, 2016 | 0.015M |
September 30, 2016 | 0.015M |
June 30, 2016 | 0.0621M |
March 31, 2016 | 0.3121M |
December 31, 2015 | 0.8211M |
September 30, 2015 | 1.269M |
June 30, 2015 | 1.788M |
March 31, 2015 | 2.205M |
December 31, 2014 | 2.575M |
September 30, 2014 | 1.781M |
June 30, 2014 | 2.316M |
March 31, 2014 | 2.632M |
December 31, 2013 | 1.732M |
September 30, 2013 | 2.370M |
June 30, 2013 | 1.430M |
March 31, 2013 | 0.4466M |
December 31, 2012 | 0.4534M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.3888M
Minimum
Dec 2022
27.75M
Maximum
Mar 2021
7.407M
Average
1.963M
Median
Jun 2020
Cash from Financing (TTM) Benchmarks
Panbela Therapeutics Inc | 26.14M |
Vera Therapeutics Inc | 133.54M |
Corbus Pharmaceuticals Holdings Inc | -2.820M |
Ensysce Biosciences Inc | 8.756M |
Elicio Therapeutics Inc | -- |